Perfluorohexane
Based on 1 Customer Validation
Perfluorohexane (AF-0150) is a perfluorocarbon. Perfluorohexane is also an enhancer of high-intensity focused ultrasound (HIFU) therapy. Perfluorohexane increases HO-1 and IL-10. Perfluorohexane exerts an antioxidant effect. Perfluorohexane alleviates lung injury induced by LPS (HY-D1056A1). Perfluorohexane improves the efficiency and precision of HIFU and reduces damage to surrounding normal tissues. Perfluorohexane can be used in the study of acute lung injury.
For research use only. We do not sell to patients.
- Purity: 98.2%
- CAS No.: 355-42-0
- Formula: C6F14
- Molecular Weight:338.04
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Perfluorohexane (12-36 h) shows no cytotoxicity to human mesothelial cells, does not induce cell activation, and does not significantly affect the expression of cell adhesion molecules ICAM-1, VCAM-1 and surfactant protein A[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (4-6 months old, weighing 250-300 g); lipopolysaccharide-induced acute lung injury model[3]
-
Dosage:10 mL/kg
-
Administration:Intraperitoneal injection; every 2 h.
-
Result:Decreased lung wet/dry weight ratio, malondialdehyde content, and myeloperoxidase activity.
Reduced tumor necrosis factor-α level and increased interleukin-10 level in bronchoalveolar lavage fluid.
Induced the expression of heme oxygenase-1.
Chemical Information
-
CAS No. 355-42-0
-
Appearance Liquid (Density: 1.665 g/cm3)
-
Molecular Weight 338.04
-
Formula C6F14
-
Color Colorless to light yellow
-
SMILES
FC(F)(C(F)(C(F)(C(F)(C(F)(C(F)(F)F)F)F)F)F)F
-
Synonyms
AF-0150
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (295.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Haufe D, et al. Effect of perfluorohexane on the expression of cellular adhesion molecules and surfactant protein A in human mesothelial cells in vitro. Artif Cells Blood Substit Immobil Biotechnol. 2011 Aug;39(4):239-46. [Content Brief]
[2]. Wang X, et al. Perfluorohexane‐encapsulated mesoporous silica nanocapsules as enhancement agents for highly efficient high intensity focused ultrasound (HIFU)[J]. Advanced Materials, 2012, 6(24): 785-791. [Content Brief]
[3]. Ge ZJ, et al. Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1. Pharmacol Rep. 2010 Jan-Feb;62(1):170-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9582 mL | 14.7911 mL | 29.5823 mL | 73.9557 mL |
| 5 mM | 0.5916 mL | 2.9582 mL | 5.9165 mL | 14.7911 mL | |
| 10 mM | 0.2958 mL | 1.4791 mL | 2.9582 mL | 7.3956 mL | |
| 15 mM | 0.1972 mL | 0.9861 mL | 1.9722 mL | 4.9304 mL | |
| 20 mM | 0.1479 mL | 0.7396 mL | 1.4791 mL | 3.6978 mL | |
| 25 mM | 0.1183 mL | 0.5916 mL | 1.1833 mL | 2.9582 mL | |
| 30 mM | 0.0986 mL | 0.4930 mL | 0.9861 mL | 2.4652 mL | |
| 40 mM | 0.0740 mL | 0.3698 mL | 0.7396 mL | 1.8489 mL | |
| 50 mM | 0.0592 mL | 0.2958 mL | 0.5916 mL | 1.4791 mL | |
| 60 mM | 0.0493 mL | 0.2465 mL | 0.4930 mL | 1.2326 mL | |
| 80 mM | 0.0370 mL | 0.1849 mL | 0.3698 mL | 0.9244 mL | |
| 100 mM | 0.0296 mL | 0.1479 mL | 0.2958 mL | 0.7396 mL |